期刊文献+

两种伊马替尼制剂的人体生物等效性 被引量:5

Bioequivalence of two kinds of imatinib preparations in healthy volunteers
原文传递
导出
摘要 目的建立人血浆中伊马替尼及其代谢物浓度的液相色谱-串联质谱法(LC-MS/MS)测定方法,并评价伊马替尼胶囊的药动学特征及生物等效性。方法 24名男性健康受试者随机分成两组,分别交叉给予伊马替尼受试制剂和参比制剂各400 mg,采用LC-MS/MS测定伊马替尼及伊马替尼代谢物的浓度,色谱柱为Thermo BDS HYPERSIL C18(100 mm×4.6 mm,2.4μm),流动相为甲醇(A)-0.1%甲酸0.2%醋酸铵溶液(B)(55:45,V/V),流速为0.7 mL·min-1;质谱采用电喷雾电离,正离子多离子反应监测模式,检测离子伊马替尼为m/z 494.10→393.85,伊马替尼代谢物为m/z 480.10→393.80,帕洛诺司琼(内标物)为m/z 297.10→109.80,估算伊马替尼及代谢物的药动学参数,评价两种制剂的人体生物等效性。结果伊马替尼受试制剂与参比制剂的各主要药动学参数:tmax分别为(2.8±1.2)h和(3.1±1.1)h,ρmax分别为(1 928.94±478.84) μg·L-1和(1 738.94±237.30) μg·L-1,t1/2分别为(17.65±1.71)h和(17.80±1.99)h,用梯形法计算AUC0-120 h分别为(37 715.80±7 625.84)μg.h.L-1和(33 961.65±6 218.64)μg.h.L-1,其代谢物的药动学参数:tmax分别为(2.8±1.2)h和(2.8±1.1)h,ρmax分别为(194.21±58.85) μg·L-1和(198.16±52.49) μg·L-1,t1/2分别为(37.59±3.53)h和(38.45±5.28)h,用梯形法计算AUC0-120 h分别为(5 274.57±1 379.87)μg.h.L-1和(5 128.31±1 119.75)μg.h.L-1。结论建立的测定方法可用于伊马替尼及其代谢物的药动学研究,伊马替尼两种制剂生物等效。 AIM To establish a LC-MS/MS method for the determination of imatinib and its metabolite in human plasma and to evaluate the pharmacokinetics and bioequivalence of imatinib capsuls in healthy volunteers. METHODS A 400 mg dose of the reference or test capsules were given to 24 healthy male volunteers in a randomized two-way crossover design and the plasma concentration of the drug was assayed by LC-MS/MS. Chromatography separation was carried on a Thermo BDS HYPERSIL C18 (100 mm×4.6 mm, 2.4 μm), with a mobile phase consisting of methanol -0.1% formic acid 0.2%ammonium acetate (55 : 45, V/V), a flow rate of 0.7 mL.min-1. Detection and quantification were performed by mass spectrometric in the multiple reaction monitoring mode with positive electrospray ionization at 494.10-'393.85 for imatinib, 480.10→393.80 for metabolite and 297.10→109.80 for oalonosetron (internal standard)
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2013年第2期145-150,共6页 Chinese Journal of New Drugs and Clinical Remedies
基金 国家科技部(2011ZXJ09202-013)
关键词 伊马替尼 代谢物 胶囊 色谱法 高压液相 串联质谱法 药动学 生物等效性 imatinib metabolite capsules chromatography, high pressure liquid tandem massspectrometry pharmacokinetics bioequivalence
  • 相关文献

参考文献5

二级参考文献43

  • 1刘毅,王颖,刘晓丹,杨平地,于晓妉.热休克蛋白90抑制剂17-AAG诱导K562细胞凋亡作用的研究[J].中华血液学杂志,2006,27(12):809-812. 被引量:7
  • 2钟大放.以加权最小二乘法建立生物分析标准曲线的若干问题[J].药物分析杂志,1996,16(5):343-346. 被引量:581
  • 3谢风祥(综述),毛海婷(审校).干扰素在肿瘤细胞凋亡信号传导通路中的作用及影响[J].国际肿瘤学杂志,2007,34(6):404-406. 被引量:2
  • 4GetzK Gi1bertM编著 邱仲潘翻译.VBA高级开发指南[M].北京:电子工业出版社,1997..
  • 5Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood,2000, 96 : 3343-3356.
  • 6Druker B J, Talpaz M, Resta DJ, et al. Efficacy and safety of a specitic inhibitor of the BCR-ABL tyrosine kinase in chronic mye- loid leukemia. N Engl J Med, 2001,344: 1031-1037.
  • 7Deininger M, O' Brien SG, Guilhot F, et al. International ran- domized study of interferon vs STI571 ( IRIS ) 8-year follow up : sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) ,2009, 114 : 1126.
  • 8Ravandi F, Kantarjian HM, Talpaz M, et al. Expression of apop- tosis proteins in chronic myelogenous leukemia: associations and significance. Cancer, 2001, 91 : 1964-1972.
  • 9Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinih mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res,2002, 8 : 935-942.
  • 10Picard S, Titier K, Etienne G, et al. Trough imatinib plasma lev- els are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 2007, 109:3496 -34~99.

共引文献45

同被引文献37

  • 1史亦丽,李美英.格列卫[J].中国新药杂志,2005,14(2):236-238. 被引量:6
  • 2Parrillo-Campiqlia S, Ercoli MC, Umpierrez 0, et al. Bioequivalence of two film-coated tablets of imatinib meylate 400 rag: a randomized, open-lable, single-dose, fasting, two- period, two-sequence crossover comparison in healthy male south American volunteers [J]. Clin Ther, 2009, 31 (10) : 2224-2232.
  • 3Zhang Y, Qiang S, Yu Z, et al. LC-MS-MS determination ofimatinib and N-desmethyl imatinib in human plasma [J]. d Chromatogr Sci, 2014, 52 (4) : 344-350.
  • 4Moreno JM, Wojnicz A, Steegman JL, et al. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma [J]. Biomed Chromatogr, 2013, 27 (4): 502-508.
  • 5Nikolova Z, Peng B, Hubert M, et al. Bioequivalence, safety,and tolerability of imatinih tablets compared with capsules [J]. Cancer Chemother Pharmaeol, 2004, 53 (5) : 433-438.
  • 6Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors [J]. Clin CaneerRes, 2002, 8(10): 3034-3038.
  • 7Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia [J]. NEnglJMed, 2001, 344: 1031-1037.
  • 8Ferlay J,Soerjomataram I,Ervik M,et al. GLOBOCAN 2012 vl.0,cancer incidence and mortality worldwide: IARC CancerBase No.ll[EB/OL]. http://globocan, iarc.fr,2014.
  • 9Cui C,Mao L,Chi Z,et al. A phase' [[ ,randomized,dou- ble-blind,placebo-controlled muhicenter trial of Endostar in patients with metastatic melanoma [J]. Mol Ther, 2013,21(7) : 1456-1463.
  • 10Chapman PB,Hauschild A,Robert C,et al. Improved sur- vival with vemurafenib in melanoma with BRAF V600E mutation[J]. N Engl J Med, 2011,364(26) : 2507-2516.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部